PTGX – Protagonist Therapeutics Inc
Float Short %
12.38
Margin Of Safety %
-22
Put/Call OI Ratio
0.1
EPS Next Q Diff
0.19
EPS Last/This Y
-6.34
EPS This/Next Y
2.93
Price
84.78
Target Price
95.92
Analyst Recom
1.23
Performance Q
13.05
Relative Volume
0.66
Beta
2.27
Ticker: PTGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | PTGX | 88.79 | 0.04 | 0.33 | 14613 |
| 2025-12-29 | PTGX | 87.85 | 0.04 | 0.68 | 14618 |
| 2025-12-30 | PTGX | 87.27 | 0.05 | 0.11 | 14657 |
| 2025-12-31 | PTGX | 87.27 | 0.05 | 0.20 | 15248 |
| 2026-01-02 | PTGX | 87.21 | 0.05 | 0.41 | 15296 |
| 2026-01-05 | PTGX | 84.78 | 0.05 | 0.12 | 15336 |
| 2026-01-06 | PTGX | 82.19 | 0.06 | 0.40 | 15434 |
| 2026-01-07 | PTGX | 82.26 | 0.06 | 0.11 | 15481 |
| 2026-01-08 | PTGX | 80.8 | 0.06 | 0.04 | 15642 |
| 2026-01-09 | PTGX | 80.33 | 0.06 | 0.22 | 15696 |
| 2026-01-12 | PTGX | 80.19 | 0.07 | 0.06 | 16120 |
| 2026-01-13 | PTGX | 81.37 | 0.07 | 0.16 | 16178 |
| 2026-01-14 | PTGX | 85.19 | 0.07 | 0.05 | 16240 |
| 2026-01-15 | PTGX | 84.76 | 0.07 | 0.11 | 16684 |
| 2026-01-16 | PTGX | 81.88 | 0.08 | 0.63 | 16622 |
| 2026-01-20 | PTGX | 83.37 | 0.10 | 0.02 | 6610 |
| 2026-01-21 | PTGX | 83.95 | 0.10 | 0.02 | 6633 |
| 2026-01-22 | PTGX | 84.77 | 0.10 | 0.03 | 6750 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | PTGX | 88.84 | -128.3 | - | -1.87 |
| 2025-12-29 | PTGX | 87.92 | -128.3 | - | -1.87 |
| 2025-12-30 | PTGX | 87.27 | -128.3 | - | -1.87 |
| 2025-12-31 | PTGX | 87.32 | -128.3 | - | -1.87 |
| 2026-01-02 | PTGX | 87.22 | -128.3 | - | -1.87 |
| 2026-01-05 | PTGX | 84.27 | -128.3 | - | -1.87 |
| 2026-01-06 | PTGX | 82.25 | -128.3 | - | -1.87 |
| 2026-01-07 | PTGX | 82.31 | -128.3 | - | -1.87 |
| 2026-01-08 | PTGX | 80.20 | -128.3 | - | -1.87 |
| 2026-01-09 | PTGX | 80.29 | -128.3 | - | -1.87 |
| 2026-01-12 | PTGX | 80.23 | -128.3 | - | -1.87 |
| 2026-01-13 | PTGX | 81.43 | -128.3 | - | -1.87 |
| 2026-01-14 | PTGX | 85.24 | -128.3 | - | -1.87 |
| 2026-01-15 | PTGX | 84.76 | -128.3 | - | -1.87 |
| 2026-01-16 | PTGX | 81.88 | -128.3 | - | -1.87 |
| 2026-01-20 | PTGX | 83.43 | -128.3 | - | -1.87 |
| 2026-01-21 | PTGX | 83.95 | -128.3 | - | -1.87 |
| 2026-01-22 | PTGX | 84.78 | -128.3 | - | -1.87 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | PTGX | -2.44 | -0.27 | 11.07 |
| 2025-12-29 | PTGX | -2.44 | -0.26 | 11.07 |
| 2025-12-30 | PTGX | -2.44 | -0.26 | 11.07 |
| 2025-12-31 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-02 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-05 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-06 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-07 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-08 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-09 | PTGX | -2.44 | -0.26 | 11.07 |
| 2026-01-12 | PTGX | -2.44 | -0.27 | 11.10 |
| 2026-01-13 | PTGX | -2.33 | -0.27 | 12.38 |
| 2026-01-14 | PTGX | -2.33 | -0.27 | 12.38 |
| 2026-01-15 | PTGX | -2.33 | -0.27 | 12.38 |
| 2026-01-16 | PTGX | -2.33 | -0.27 | 12.38 |
| 2026-01-20 | PTGX | -2.33 | -0.44 | 12.38 |
| 2026-01-21 | PTGX | -3.68 | -0.44 | 12.38 |
| 2026-01-22 | PTGX | -3.68 | -0.44 | 12.38 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.62
Avg. EPS Est. Current Quarter
-0.56
Avg. EPS Est. Next Quarter
-0.43
Insider Transactions
-3.68
Institutional Transactions
-0.44
Beta
2.27
Average Sales Estimate Current Quarter
34
Average Sales Estimate Next Quarter
18
Fair Value
65.85
Quality Score
53
Growth Score
59
Sentiment Score
90
Actual DrawDown %
12.2
Max Drawdown 5-Year %
-85.8
Target Price
95.92
P/E
133.86
Forward P/E
101.21
PEG
P/S
25.34
P/B
8.2
P/Free Cash Flow
83.2
EPS
0.63
Average EPS Est. Cur. Y
-1.87
EPS Next Y. (Est.)
1.06
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
21.94
Relative Volume
0.66
Return on Equity vs Sector %
-20.1
Return on Equity vs Industry %
-4.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 128
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading